Under a tenth of patients that would benefit from weight-loss injections like Wegovy can access them, caution the WHO as it issues its initial guidance on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for broader and more equitable availability to GLP-1 medication.
Based on forecasts, over two billion will be obese by 2030 unless action is taken.
"Our latest guidance acknowledges that obesity is a lifelong illness that can be managed with holistic and ongoing care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are key barriers to broad availability to the jabs that can aid individuals in losing considerable body mass, notes the body.
GLP-1 Therapy Scarcity
Even under the present best projected outlook, the supply of such drugs could only cover about 100 million people – fewer than 10% of the global need, per the health organization.
The advice encourages nations and manufacturers to expand access, by strategies like patent sharing.
Exclusive production rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
How Weight-Loss Injections Operate
These medications imitate a natural hormone to slow digestion, reduce hunger and increase satiety so users eat less.
Patients usually start to lose weight in the initial weeks of commencing the once-weekly jabs.
Studies points to patients may regain a significant portion within a year of stopping the drug, as their normal appetite come back.
Being above a healthy weight increases your chance for experiencing health problems, such as diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight concerns individuals in all nations and was associated with over three and a half million deaths worldwide in 2024, as per the health agency.
